JP2021510818A5 - - Google Patents

Info

Publication number
JP2021510818A5
JP2021510818A5 JP2020538841A JP2020538841A JP2021510818A5 JP 2021510818 A5 JP2021510818 A5 JP 2021510818A5 JP 2020538841 A JP2020538841 A JP 2020538841A JP 2020538841 A JP2020538841 A JP 2020538841A JP 2021510818 A5 JP2021510818 A5 JP 2021510818A5
Authority
JP
Japan
Prior art keywords
cancer
mmol
compound according
disease
compound
Prior art date
Application number
JP2020538841A
Other languages
English (en)
Japanese (ja)
Other versions
JP7346425B2 (ja
JP2021510818A (ja
JPWO2019140188A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/013193 external-priority patent/WO2019140188A1/en
Publication of JP2021510818A publication Critical patent/JP2021510818A/ja
Publication of JP2021510818A5 publication Critical patent/JP2021510818A5/ja
Publication of JPWO2019140188A5 publication Critical patent/JPWO2019140188A5/ja
Priority to JP2023143506A priority Critical patent/JP7692963B2/ja
Application granted granted Critical
Publication of JP7346425B2 publication Critical patent/JP7346425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020538841A 2018-01-11 2019-01-11 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤 Active JP7346425B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023143506A JP7692963B2 (ja) 2018-01-11 2023-09-05 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616253P 2018-01-11 2018-01-11
US62/616,253 2018-01-11
PCT/US2019/013193 WO2019140188A1 (en) 2018-01-11 2019-01-11 Inhibitors of dihydroceramide desaturase for treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023143506A Division JP7692963B2 (ja) 2018-01-11 2023-09-05 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤

Publications (4)

Publication Number Publication Date
JP2021510818A JP2021510818A (ja) 2021-04-30
JP2021510818A5 true JP2021510818A5 (https=) 2022-01-19
JPWO2019140188A5 JPWO2019140188A5 (https=) 2022-01-19
JP7346425B2 JP7346425B2 (ja) 2023-09-19

Family

ID=67219929

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020538841A Active JP7346425B2 (ja) 2018-01-11 2019-01-11 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤
JP2023143506A Active JP7692963B2 (ja) 2018-01-11 2023-09-05 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023143506A Active JP7692963B2 (ja) 2018-01-11 2023-09-05 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤

Country Status (8)

Country Link
US (3) US11597715B2 (https=)
EP (1) EP3737361A4 (https=)
JP (2) JP7346425B2 (https=)
KR (1) KR20250057925A (https=)
CN (1) CN111787916B (https=)
AU (1) AU2019207887B2 (https=)
CA (1) CA3087729A1 (https=)
WO (1) WO2019140188A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
US11135207B2 (en) 2016-12-13 2021-10-05 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN111787916B (zh) * 2018-01-11 2023-09-05 森陶鲁斯治疗公司 用于治疗疾病的二氢神经酰胺去饱和酶抑制剂
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
MX2021008903A (es) * 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
WO2020168294A1 (en) 2019-02-15 2020-08-20 Lysosomal And Rare Disorders Research And Treatment Center, Llc Methods and compositions for treating lysosomal storage disorders: ambroxol as treatment agent for mucopolysaccharidoses iii (sanfilippo syndrome)
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2022115612A1 (en) * 2020-11-25 2022-06-02 Lysosomal and Rare Disorders Research and Treatment Center, Inc. Inhibition of caspase pathway as a treatment for lysosomal storage disorders
EP4378938A4 (en) * 2021-07-29 2025-04-02 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. NEW PARP7 INHIBITOR AND USE THEREOF
US20240343727A1 (en) * 2021-08-17 2024-10-17 InventisBio Co., Ltd. Pyridazinone or pyridinone compounds, preparation methods and uses thereof
CN120136787A (zh) * 2023-12-13 2025-06-13 青岛清原化合物有限公司 一种吡唑取代的芳基硫化物类化合物及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62249945A (ja) 1986-04-23 1987-10-30 Fuji Photo Film Co Ltd ハイドロキノン・モノエステル類の合成方法
US6124299A (en) 1997-02-24 2000-09-26 Zymogenetics, Inc. Calcitonin mimetics
FR2770131A1 (fr) 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6894063B2 (en) 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
ES2170030B1 (es) 2000-12-19 2003-11-16 Consejo Superior Investigacion Inhibidores de la dihidroceramida desaturasa.
US6667319B2 (en) 2001-07-26 2003-12-23 Schering-Plough Corporation Neuropeptide Y Y5 receptor antagonists
EP1636187A1 (en) 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
AU2004247320A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase
US7129235B2 (en) 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
JP2007501805A (ja) 2003-08-08 2007-02-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピリジルピペラジニルウレア
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
US8143257B2 (en) 2004-11-23 2012-03-27 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting VEGF production
AR055831A1 (es) 2004-12-30 2007-09-12 Janssen Pharmaceutica Nv Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
ES2528674T3 (es) * 2005-02-17 2015-02-11 Astellas Pharma Inc. Piperidina y carboxilatos de piperacina como inhibidores de FAAH
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US20100048714A1 (en) 2006-06-19 2010-02-25 University Of Utah Research Foundation Methods and Compositions Related to Inhibition of Ceramide Synthesis
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
KR20110065417A (ko) 2008-01-03 2011-06-15 욱크하르트 리미티드 파라세타몰 및 이부프로펜을 포함하는 경구 약제학적 현탁액
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
FR2939135B1 (fr) 2008-12-02 2010-12-03 Galderma Res & Dev Nouveaux composes 4-(azacycloalkyl)-benzene-1,3-diol comme inhibiteurs de la tyrosinase, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
CN102365275B (zh) 2009-01-28 2014-09-24 里格尔药品股份有限公司 羧酰胺化合物及其使用方法
JP2010195688A (ja) 2009-02-23 2010-09-09 Shionogi & Co Ltd Npyy5受容体拮抗作用を有するアミド及びウレア誘導体
EP2518064A1 (en) 2009-12-25 2012-10-31 Mochida Pharmaceutical Co., Ltd. Novel aryl urea derivative
CN103172635B (zh) * 2011-12-21 2016-04-27 上海医药工业研究院 哌嗪或哌啶类化合物、其盐、中间体、制备方法及应用
EP3043822A1 (en) * 2013-09-11 2016-07-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compositions for preparing cardiomyocytes
BR112018076258A2 (pt) 2016-06-30 2019-03-26 Basilea Pharm Int Ag inibidores mitocondriais para o tratamento de distúrbios de proliferação
US11135207B2 (en) * 2016-12-13 2021-10-05 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
CN111787916B (zh) * 2018-01-11 2023-09-05 森陶鲁斯治疗公司 用于治疗疾病的二氢神经酰胺去饱和酶抑制剂

Similar Documents

Publication Publication Date Title
JP7692963B2 (ja) 疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤
JP2021510818A5 (https=)
US11771684B2 (en) Inhibitors of dihydroceramide desaturase for treating disease
US7834004B2 (en) Sulfonyl-substituted bicyclic compounds as modulators of PPAR
CN108727363B (zh) 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
EP3157917A1 (en) Compounds, compositions and methods of increasing cftr activity
BR112021000395A2 (pt) Compostos imunomoduladores diméricos contra mecanismos baseados em cereblon
AU2015272560A1 (en) Novel anticancer agent
TW201100400A (en) Piperazine compound capable of inhibiting prostaglandin d synthase
EP3578549A1 (en) Heterocyclic compound
JPWO2019140188A5 (https=)
EP4499148A1 (en) Cyclin-dependent kinase 9 (cdk9) degraders and methods of using thereof
GB2467561A (en) Dual calpain-ROS inhibitors
KR102798144B1 (ko) 질병 치료를 위한 디하이드로세라마이드 불포화화효소의 저해제
JP2025526814A (ja) 化合物、それを含む医薬組成物及びその用途
WO2023030170A1 (zh) 基于nampt靶蛋白的蛋白降解化合物及其应用
CN117120443A (zh) 作为腺苷A2a受体拮抗剂的化合物及包含其的药物组合物
HK1236029A1 (en) Naphthofuran derivatives for use as anticancer agents
HK1236029B (en) Naphthofuran derivatives for use as anticancer agents